Photodiagnosis and Photodynamic Therapy
Volume 3, Issue 4 , Pages 234-246 , December 2006

Prostate PDT dosimetry

References 

  1. Jemal A, Seigel R, Ward E, et al. Cancer Statistics, 2006. CA-A Cancer J Clin. 2006;56:106–130
  2. Catalona WJ. Screening for early detection. Lancet. 1996;347:883–884
  3. Dougherty TJ, Gomer DJ, Henderson BW, et al. Photodynamic Therapy. J Natl Cancer Inst. 1998;90:889–905
  4. Ornstein DKO, Herschman JD, Andriole GL. Evaluation and management of the man who has failed primary curative therapy for prostate cancer. Urol Clin North Am. 1998;25:591–601
  5. Nathan TR, Whitelaw DE, Chang SC, et al. Photodynamic therapy for prostate cancer recurrence after radiotherapy: a Phase I study. J Urol. 2002;168:1427–1432
  6. Zaak D, Sroka R, Hoppner M, et al. Photodynamic therapy by means of 5-ALA induced PPIX in human prostate—preliminary results. Med Laser Appl. 2003;18:91–95
  7. Stripp DCH, Mick R, Zhu TC, et al. Phase I trial of Motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. Proc SPIE. 2004;5315:88–99
  8. Verigos K, Stripp DCH, Mick R, et al. Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. J Environ Pathol Toxicol Oncol. 2006;25(1–2):373–388
  9. Weersink RA, Bogaards A, Gertner M, et al. Techniques for delivery and monitoring of TOOKAD (WST09)-mediated photodynamic therapy of the prostate: clinical experience and practicalities. J Photochem Photobiol B. 2005;79(3):211–222
  10. Weersink RA, Forbes J, Bisland S, et al. Assessment of cutaneous photosensitivity of TOOKAD (WST09) in preclinical animal models and in patients. Photochem Photobiol. 2005;81(1):106–113
  11. Pinthus JH, Bogaards A, Weersink R, Wilson BC, Trachtenberg J. Photodynamic therapy for urological malignancies: past to current approaches. J Urol. 2006;175(4):1201–1207
  12. Arnfield MR, Chapman JD, Tulip J, Fenning MC, McPhee MS. Optical properties of experimental prostate tumors in vivo. Photochem Photobiol. 1993;57(2):306–311
  13. Chen Q, Wilson BC, Shetty SD, Patterson MS, Cerny JC, Hetzel FW. Changes in in vivo optical properties and light distributions in normal canine prostate during photodynamic therapy. Radiat Res. 1997;147(1):86–91
  14. Lee LK, Whitehurst C, Chen Q, Pantelides ML, Hetzel FW, Moore JV. Interstitial photodynamic therapy in the canine prostate. Br J Urol. 1997;80(6):898–902
  15. Selman SH, Keck RW. The effect of tranurethral light on the canine prostate after sensitization with the photosensitizer tin (II) etiopurpurin dichloride: a pilot study. J Urol. 1994;152:2129–2132
  16. Selman SH, Keck RW, Hampton JA. Transperineal photodynamic ablation of the canine prostate. J Urol. 1996;156:258–260
  17. Selman SH, Albrecht D, Keck RW, Brennan P, Kondo S. Studies of tin ethyl etiopurpurin photodynamic therapy of the canine prostate. J Urol. 2001;165:1795–1801
  18. Hsi A, Kapatkin AS, Strandberg J, et al. Photodynamic therapy in the canine prostate using Motexafin lutetium. Clin Cancer Res. 2001;7:651–660
  19. Chang SC, Buonaccorsi G, MacRobert A, Brown SG. Interstitial photodynamic therapy in the canine prostate with disulfonated aluminum phthalocyanine and 5-aminolevulinic acid-induced photoporphyrin IX. Prostate. 1997;32:89–98
  20. Chang SC, Buonaccorsi G, MacRobert A, Bown SG. Interstitial and transurethral photodynamic therapy of the canine prostate using meso-tetra-(m-hydroxyphenyl) chlorin. Int J Cancer. 1996;67:555–562
  21. Dimofte A, Finlay JC, Zhu TC. A method for determination of the absorption and scattering properties interstitially in turbid media. Phys Med Biol. 2005;50:2291–2311
  22. Zhu TC, Dimofte A, Finlay JC, et al. Optical properties of human prostate at 732nm measured in vivo during Motexafin lutetium-mediated photodynamic therapy. Photochem Photobiol. 2005;81:96–105
  23. Finlay JC, Zhu TC, Dimofte A, et al. In vivo determination of the absorption and scattering spectra of the human prostate during photodynamic therapy. Proc SPIE. 2004;5315:132–142
  24. Wang HW, Zhu TC, Putt ME, et al. In-vivo broadband reflectance measurements of light penetration depth, blood oxygenation, hemoglobin concentration, and drug concentration in human tissues before and after photodynamic therapy. J Biomed Opt. 2005;10(1–13):
  25. Finlay JC, Zhu TC, Dimofte A, et al. In vivo measurement of fluorescence emission in the human prostate during photodynamic therapy. Proc SPIE. 2005;5689:299–310
  26. Finlay JC, Zhu TC, Dimofte A, Stripp D, Malkowicz SB, Busch TM, Hahn SM. Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy. Photochem Photobiol 2006, submitted for publication.
  27. Pass HI. Photodynamic therapy in oncology: mechanisms and clinical use. J Natl Cancer Inst. 1993;85(6):443–456
  28. Ochsner M. Photophysical and photobiological processes in the photodynamic therapy of tumours. J Photochem Photobiol B. 1997;39(1):1–18
  29. Foote CS. Photosenstizied oxidations and the role of singlet oxygen. Acc Chem Res. 1967;1:104–110
  30. Niedre M, Patterson MS, Wilson BC. Direct near-infrared luminescence detection of singlet oxygen generated by photodynamic therapy in cells in vitro and tissues in vivo. Photochem Photobiol. 2002;75(4):382–391
  31. Niedre MJ, Patterson MS, Giles A, Wilson BC. Imaging of photodynamically generated singlet oxygen luminescence in vivo. Photochem Photobiol. 2005;81(4):941–943
  32. Mang TS, Dougherty TJ, Potter WR, Boyle DG, Somer S, Moan J. Photobleaching of porphyrins used in photodynamic therapy and implications for therapy. Photochem Photobiol. 1987;45:501–506
  33. Jacques SL, Joseph R, Gofstein G. How photobleaching effects dosimetery and fluorescence monitoring of PDT in turbid media. Proc SPIE. 1993;1881:168–179
  34. Wilson BC, Patterson MS, Lilge L. Implicit and explicit dosimetry in photodynamic therapy: a new paradigm. Lasers Med Sci. 1997;12:182–199
  35. Georgekoudi I, Foster TH. Singlet oxygen-versus nonsinglet oxygen-mediated mechanisms of sensitizer photobleaching and their effects on photodynamic dosimetry. Photochem Photobiol. 1998;67:612–625
  36. Georgakoudi I, Nichols MG, Foster TH. The mechanism of Photofrin photobleaching and its consequences for photodynamic dosimetry. Photochem Photobiol. 1997;65:135–144
  37. Patterson MS, Wilson BC, Graff R. In vivo tests of the concept of photodynamic threshold dose in normal rat liver photosensitized by aluminum chlorosulphonated phthalocyanine. Photochem Photobiol. 1990;51:343–349
  38. Hetzel FW, Brahmavar SM, Chen Q, Jacques SL, Patterson MS, Wilson BC, et al. Photodynamic Therapy Dosimetry, AAPM Report No. 88. Madison, WI: Med Phys Publishing; 2005;
  39. Finlay JC, Mitra S, Foster TH. Photobleaching kinetics of Photofrin in vivo and in multicell tumor spheroids indicate multiple simultaneous bleaching mechanisms. Phys Med Biol. 2004;49:4837–4860
  40. Star WM. Light dosimetry in vivo. Phys Med Biol. 1997;42:763–787
  41. Dimofte A, Zhu TC, Hahn SM, Lustig RA. In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer. Lasers Surg Med. 2002;31(5):305–312
  42. Baas P, Murrer L, Zoetmulder FA, Stewart FA, Ris HB, van Zandwijk N, et al. Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies. Br J Cancer. 1997;76(6):819–826
  43. Solonenko M, Zhu TC, Vulcan TG. Commissioning of the isotropic light dosimetry system for photodynamic therapy. Med Phys. 1999;26:1124
  44. van Staveren HJ, Marijnissen HPA, Aalders MC, Star WM. Construction, quality assurance, and calibration of spherical isotropic fibre optic light diffusers. Lasers Med Sci. 1995;10:137–147
  45. Vulcan TG, Zhu TC, Rodriguez CE, et al. Comparison between isotropic and nonisotropic dosimetry systems during intraperitoneal photodynamic therapy. Lasers Surg Med. 2000;26(3):292–301
  46. Wainwright M. Photodynamic antimicrobial chemotherapy (PACT). J Antimicrob Chemother. 1998;42(1):13–28
  47. Momma T, Hamblin MR, Wu HC, Hasan T. Photodynamic therapy of orthotopic prostate cancer with benzoporphyrin derivative: local control and distant metastasis. Cancer Res. 1998;58(23):5425–5431
  48. Chen B, Pogue BW, Zhou X, et al. Effect of of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model. Clin Cancer Res. 2005;11(2 Part 1):720–727
  49. Zhu TC, Li J, Finlay JC, et al. In-vivo light dosimetry of interstitial PDT of human prostate. Proc SPIE. 2006;6139(61390):L1–L11
  50. Li J, Zhu TC, Finlay JC. Study of light fluence rate distribution in photodyanmic therapy using finite-element method. Proc SPIE. 2006;6139(61390):M1–M8
  51. Zhu TC, Hahn SM, Kapatkin AS, et al. In-vivo optical properties of normal canine prostate at 732nm using motexafin lutetium-mediated photodynamic therapy. Photochem Photobiol. 2003;77:81–88
  52. Ishimaru A. Wave propagation and scattering in random media. New York: IEEE Press; 1997;
  53. Wilson BC, Patterson MS. The determination of light fluence distribution in photodynamic therapy. In:  Kessel D editors. Photodynamic therapy of neoplastic disease. Boca Raton: CRC Press Inc.; 1990;p. 129–144
  54. Jacques S. Light distributions from point, line and plane sources for photochemical reactions and fluorescence in turbid biological tissues. Photochem Photobiol. 1998;67:23–32
  55. Nakai T, Nishimura G, Yamamoto K, Tamura M. Expression of optical diffusion coefficient in high-absorption turbid media. Phys Med Biol. 1997;42:2541–2549
  56. Storn R, Price K. Differential evolution - a simple and efficient heuristic for global optimization over continuous spaces. J Global Optimization. 1997;11:341–359
  57. Zhu TC, Bjarngard BE, Xiao Y, Yang CJ. Modeling the output ratio in air for megavoltage photon beams. Med Phys. 2001;28(6):925–937
  58. Zhu TC, Finlay JC, Hahn SM. Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during Motexafin lutetium-mediated photodynamic therapy. J Photochem Photobiol B. 2005;79:231–241
  59. Diamond KR, Patterson MS, Farrell TJ. Quantification of fluorophore concentration in tissue-simulating media by fluorescence measurements with a single optical fiber. Appl Opt. 2003;42:2436–2442
  60. Liu H, Boas DA, Zhang Y, Yodh AG, Chance B. Determination of optical properties and blood oxygenation in tissue using continuous near-infrared light. Phys Med Biol. 1995;40:1983–1993
  61. Kienle A, Lilge L, Patterson MS, Hibst R, Steiner RA, Wilson BC. Spatially resolved absolute diffuse reflectance measurements for noninvasive determination of the optical scattering and absorptions of biological tissue. Appl Opt. 1996;35:2304–2313
  62. Doornbos RMP, Lang R, Aalders MC, Cross FW, Sterenborg HJ. The determination of in vivo human tissue optical properties and absolute chromophore concentrations using spatially resolved steady-state diffuse reflectance spectroscopy. Phys Med Biol. 1999;44:967–981
  63. Solonenko M, Cheung R, Busch TM, et al. In-vivo reflectance measurement of motexafin lutetium uptake, optical properties, and oxygenation of canine large bowels, kidneys, and prostates. Phys Med Biol. 2002;47:857–873
  64. Nichols MG, Foster TH. Oxygen diffusion and reaction kinetics in the photodynamic therapy of multicell tumour spheroids. Phys Med Biol. 1994;39:2161–2181
  65. Tromberg BJ, Orenstein A, Kimel S, et al. In vivo tumor oxygen tension measurements for the evaluation of the efficiency of photodynamic therapy. Photochem Photobiol. 1990;52:375–385
  66. Henderson BW, Busch TM, Vaughan LA, et al. Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate. Cancer Res. 2000;60:525–529
  67. Robinson DJ, de Bruijn HS, van der Veen N, Stringer MR, Brown SB, Star WM. Fluorescence photobleaching of ALA-induced protoporphyrin IX during photodynamic therapy of normal hairless mouse skin: the effect of light dose and irradiance and the resulting biological effect. Photochem Photobiol. 1998;67:140–149
  68. Robinson DJ, de Bruijn HS, van der Veen N, Stringer MR, Brown SB, Star WM. Protoporphyrin IX fluorescence photobleaching during ALA-mediated photodynamic therapy of UVB-induced tumors in hairless mouse skin. Photochem Photobiol. 1999;69:61–70
  69. Finlay JC, Conover DL, Hull EL, Foster TH. Porphyrin bleaching and PDT-induced spectral changes are irradiance dependent in ALA-sensitized normal rat skin in vivo. Photochem Photobiol. 2001;73:54–63
  70. Finlay JC, Mitra S, Foster TH. In vivo mTHPC photobleaching in normal rat skin exhibits unique irradiance-dependent features. Photochem Photobiol. 2002;75:282–288
  71. Finlay JC, Foster TH. Hemoglobin oxygen saturations in phantoms and in vivo from measurements of steady state diffuse reflectance at a single, short source-detector separation. Med Phys. 2004;31(7):1949–1959
  72. Altschuler MD, Zhu TC, Li J, Hahn SM. Optimized interstitial PDT prostate treatment planning with the Cimmino feasibility algorithm. Med Phys. 2005;32(12):3524–3536
  73. Yu G, Durduran T, Zhou C, et al. Noninvasive monitoring of murine tumor blood flow during and after photodynamic therapy provides early assessment of therapeutic efficacy. Clin Cancer Res. 2005;11(9):3543–3552
  74. Wang HW, Putt ME, Emanuele MJ, et al. Treatment-induced changes in tumor oxygenation predict photodynamic therapy outcome. Cancer Res. 2004;64(20):7553–7561
  75. Yu G, Durduran T, Zhou C, Zhu TC, Finlay JC, Busch TM, et al. Real-time in situ monitoring of human prostate photodynamic therapy with diffuse light. Photochem Photobiol. 2006;[Epub ahead of print]
  76. Chen Q, Hetzel FW. Laser dosimetry studies in the prostate. J Clin Laser Med Surg. 1998;16(1):9–12
  77. Chapman JD, McPhee MS, Walz N, et al. Nuclear magnetic resonance spectroscopy and sensitizer-adduct measurements of photodynamic therapy-induced ischemia in solid tumors. J Natl Cancer Inst. 1991;83(22):1650–1659
  78. Lapointe D, Brasseur N, Cadorette J, et al. High-resolution PET imaging for in vivo monitoring of tumor response after photodynamic therapy in mice. J Nucl Med. 1999;40(5):876–882
  79. Igbaseimokumo U. Quantification of in vivo Photofrin uptake by human pituitary adenoma tissue. J Neurosurg. 2004;101(2):272–277
  80. Marks PV, Belchetz PE, Saxena A, et al. Effect of photodynamic therapy on recurrent pituitary adenomas: clinical phase I/II trial—an early report. Br J Neurosurg. 2000;14(4):317–325
  81. Wiedmann M, Berr F, Schiefke I, et al. Photodynamic therapy in patients with non-resectable hilar cholangiocarcinoma: 5-year follow-up of a prospective phase II study. Gastrointest Endosc. 2004;60(1):68–75
  82. Wiedmann M, Caca K, Berr F, et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study. Cancer. 2003;97(11):2783–2790
  83. Cuenca RE, Allison RR, Sibata C, Downie GH. Breast cancer with chest wall progression: treatment with photodynamic therapy. Ann Surg Oncol. 2004;11(3):322–327
  84. Touma D, Yaar M, Whitehead S, Konnikov N, Gilchrest BA. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol. 2004;140(1):33–40
  85. Ericson MB, Sandberg C, Stenquist B, et al. Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome. Br J Dermatol. 2004;151(6):1204–1212
  86. Kelty CJ, Ackroyd R, Brown NJ, Brown SB, Reed MW. Comparison of high- vs low-dose 5-aminolevulinic acid for photodynamic therapy of Barrett's esophagus. Surg Endosc. 2004;18(3):452–458
  87. Hage M, Siersema PD, van Dekken H, et al. 5-Aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial. Gut. 2004;53(6):785–790
  88. Hage M, Siersema PD, Vissers KJ, et al. Molecular evaluation of ablative therapy of Barrett's oesophagus. J Pathol. 2005;205(1):57–64
  89. Cappugi P, Mavilia L, Campolmi P, Reali EF, Mori M, Rossi R. New proposal for the treatment of nodular basal cell carcinoma with intralesional 5-aminolevulinic acid. J Chemother. 2004;16(5):491–493
  90. Loning M, Diddens H, Kupker W, Diedrich K, Huttmann G. Laparoscopic fluorescence detection of ovarian carcinoma metastases using 5-aminolevulinic acid-induced protoporphyrin IX. Cancer. 2004;100(8):1650–1656
  91. Frei KA, Bonel HM, Frick H, Walt H, Steiner RA. Photodynamic detection of diseased axillary sentinel lymph node after oral application of aminolevulinic acid in patients with breast cancer. Br J Cancer. 2004;90(4):805–809
  92. Webber J, Fromm D. Photodynamic therapy for carcinoma in situ of the anus. Arch Surg. 2004;139(3):259–261
  93. Dragieva G, Hafner J, Dummer R, et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation. 2004;77(1):115–121
  94. Dragieva G, Prinz BM, Hafner J, et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol. 2004;151(1):196–200
  95. Rhodes LE, de Rie M, Enstrom Y, et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol. 2004;140(1):17–23
  96. Lui H, Hobbs L, Tope WD, et al. Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light-emitting diodes: two-year results evaluating tumor response and cosmetic outcomes. Arch Dermatol. 2004;140(1):26–32
  97. Azab M, Boyer DS, Bressler NM, et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol. 2005;123(4):448–457
  98. Hopper C, Kubler A, Lewis H, Tan IB, Putnam G. mTHPC-mediated photodynamic therapy for early oral squamous cell carcinoma. Int J Cancer. 2004;111(1):138–146
  99. Lou PJ, Jager HR, Jones L, Theodossy T, Bown SG, Hopper C. Interstitial photodynamic therapy as salvage treatment for recurrent head and neck cancer. Br J Cancer. 2004;91(3):441–446
  100. Shikowitz MJ, Abramson AL, Steinberg BM, et al. Clinical trial of photodynamic therapy with meso-tetra (hydroxyphenyl) chlorin for respiratory papillomatosis. Arch Otolaryngol Head Neck Surg. 2005;131(2):99–105
  101. Chou TM, Woodburn KW, Cheong WF, et al. Photodynamic therapy: applications in atherosclerotic vascular disease with motexafin lutetium. Catheter Cardiovasc Interv. 2002;2002(3):387–394
  102. Kereiakes DJ, Szyniszewski AM, Wahr D, et al. Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results. Circulation. 2003;108(11):1310–1315
  103. Lustig RA, Vogl TJ, Fromm D, et al. A multicenter Phase I safety study of intratumoral photoactivation of talaporfin sodium in patients with refractory solid tumors. Cancer. 2003;98(8):1767–1771

PII: S1572-1000(06)00115-3

doi: 10.1016/j.pdpdt.2006.08.002

Photodiagnosis and Photodynamic Therapy
Volume 3, Issue 4 , Pages 234-246 , December 2006

Article Tools

* Image Usage & Resolution